Introduction
Head and neck squamous cell carcinoma (HNSCC) is a frequently fatal malignancy of the upper aerodigestive epithelium. While human papilloma virus (HPV) infection is an increasingly common etiologic factor in a subset of HNSCCs (1) , cancers of the oral cavity in particular are infrequently associated with expression of viral genes. (2) Primary risk factors for development of HPV-negative HNSCC include exposure to environmental carcinogens, particularly tobacco and alcohol. These carcinogens contribute to the heterogeneous accumulation of genetic and epigenetic lesions throughout the oral mucosa, leading to "field cancerization" in which the entire tissue may be pre-cancerous and at elevated risk of malignant transformation. (5) Importantly, these murine cancers share pathologic and biochemical features with tobacco-related human HNSCC, including epidermal growth factor receptor (EGFR) overexpression and downregulation of p16. (5, 6) Promising targets of interest in prior 4-NQO chemoprevention studies include cyclooxygenase-2 (COX-2) (7, 8) and EGFR (9) . Targeting of COX-2 or EGFR, however, has not proven effective in clinical trials of patients with oral premalignancies due to toxicity of the agents used and the lack of predictive biomarkers (10) (11) (12) .
Development of alternate chemopreventive approaches that target distinct molecular pathways is therefore warranted.
Signal transducer and activator of transcription 3 (STAT3) is a proto-oncogenic transcription factor that is ubiquitously hyperactivated in HNSCC and other cancers, and represents a rational target for pharmacologic inhibition. 
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other proteins (14) , the chemopreventive effects of a direct STAT3 inhibitor has not been tested. We therefore investigated the efficacy of the small molecule STAT3 SH2 domain inhibitor Stattic (15) 
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Methods and Materials
Study Design and Statistics
Based upon our previous experience with the 4-NQO model (9) , this study was designed to detect a reduction in dysplastic or cancerous lesions from 80% in the control group to 25% in the treatment group with 80% power at α = 0.025. This design required 12 mice per treatment group. At least 13 mice per group were included due to the potential for toxicity. Tumors were assigned a score from 0 to 6, reflecting increasing histologic severity from normal tissue (score = 0) to invasive SCC (score = 6). This disease severity was analyzed by a two way analysis of variance with interaction. Due to lack of interaction and negligible impact of mouse genotype, the data were combined across mouse types to test for differences in treatment effect using a two-tailed Wilcoxon test. pSTAT3 and total STAT3 were quantified by immunohistochemistry (IHC) and analyzed for effects of severity score, treatment group, and mouse genotype by linear regression.
Animals and Treatments
All animal manipulations were performed in accordance with a protocol approved by the Institutional Animal Care and Use Committee at the University of Pittsburgh. C57BL/6J mice lacking the intracellular catalytic domain of PTPRT (PTPRT KO) were obtained from Zhenghe Wang (Case Western Reserve University, Cleveland, OH) with the consent of the RIKEN BioResource Center (Japan). Age-matched wild-type (WT) C57BL/6J mice were obtained from Jackson Laboratories (Bar Harbor, ME). All mice received 4-NQOcontaining water as previously described (9) for 12 weeks. Briefly, 50 mg/mL 4-NQO (Sigma Aldrich, St. Louis, MO) stock solutions were prepared in DMSO and stored at -20°C. Weekly, 4-NQO stock was further diluted to 12.5 mg/mL in propylene glycol before addition of 2 mL 4-NQO solution to 250 mL fresh drinking water (100 µg/mL final concentration).
A timeline of experimental treatments is depicted in Figure 1A . At experiment initiation, a subset of mice were randomly assigned to vehicle (sterile PBS) or 50 mg/kg Stattic (Selleck Chemicals, Houston, TX) by oral gavage five times weekly. After three weeks, vehicle/Stattic treatment was suspended due to unforeseen toxicity when combined with 4-NQO, and 4-NQO administration was continued alone. After a subsequent 
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round of births, a second group of age-matched mice received only 4-NQO. At the end of the 12-week 4-NQO administration period for each group, mice in the second 4-NQO round were randomized to receive vehicle or Stattic as above, while mice in the discontinued combined treatment group received the same treatment as previously (vehicle or Stattic). After an additional 12 weeks of vehicle or Stattic treatment, mice were sacrificed followed by excision of tongues which were immediately fixed in 10% formalin.
Histology
Tissue was processed and analyzed as previously described. (16) 
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Results
Combined toxicity of 4-NQO and Stattic
We initially sought to determine the chemopreventive activity of Stattic when administered simultaneously with a chemical carcinogen. We therefore treated 33 mice with vehicle or 50 mg/kg Stattic by oral gavage five times weekly beginning concurrently with 4-NQO administration ad libitum in drinking water as depicted in Figure   1A . Several adverse events, including deaths, were observed within the first three weeks of combined treatment with 4-NQO and Stattic ( Figure 1B) . On day 6 post-treatment initiation, one WT mouse receiving Stattic died. An additional two WT mice receiving Stattic died on day 19. On day 20, one KO mouse was observed with a body condition score of 2, indicating poor health. (19) As all of the observed toxicities to this point occurred in mice receiving Stattic/4-NQO with no apparent toxicity in mice treated with vehicle/4-NQO, we suspended further vehicle or Stattic administration until completion of 4-NQO treatment at 12 weeks. After cessation of treatment, the mouse with poor body condition recovered rapidly, and no further toxicity was observed during the 12-week period. Table 1 outlines the number of surviving mice in each group that received 3 weeks of vehicle or Stattic at the beginning of the experiment and which were included for further analysis.
4-NQO treatment induces diverse neoplasias
A second group of 28 age-matched mice received 12 weeks of 4-NQO (100 µg/mL) ad libitum followed by 12 weeks of Stattic (50 mg/kg) or vehicle control. At the end of this 24-week period, mice were sacrificed and tongues were harvested for analysis. The final number of mice per group is indicated in Table 2 . A head and neck cancer pathologist (LW) blinded to the treatment groups analyzed each tongue and determined disease severity corresponding to no evidence of disease, squamous papillary hyperplasia, mild dysplasia, mild to moderate dysplasia, moderate to severe dysplasia, severe dysplasia, SCC in situ, or invasive SCC (representative images shown in Figure 2A) . In WT mice that received vehicle (n = 13), every tongue displayed mild dysplasia or worse, with 7 mice (53.8%) displaying SCC of which 4 (30.8%) were invasive. This analysis indicates that our 4-NQO regimen produces dysplasia of diverse severity in C57BL/6J mice. 
We first sought to test the hypothesis that PTPRT KO mice would be more susceptible than WT mice to 4-NQO-induced carcinogenesis, as well as more sensitive to Stattic-mediated chemoprevention. To that end, we began our analysis of the spectrum of dysplasias in WT and KO mice by crossing two types of mouse (WT or KO) with the two treatment groups (Stattic or vehicle) ( Figure 3A) . Table 2 indicates the total number of mice in each group included in this analysis. Using a rank transformation statistic to analyze our semi-quantitative ordered pathology scores, we detected no significant effect of mouse genotype (WT versus KO; P = 0.9985) and no significant interaction between mouse genotype and treatment (P = 1.0), indicating that PTPRT status was not a major determinant of susceptibility to tumor formation or sensitivity to Stattic-mediated chemoprevention in this model (Supplemental Figure S1 ).
Stattic abrogates 4-NQO tumorigenesis
Because responses in WT and KO mice were statistically indistinguishable, we pooled all vehicle or Stattictreated mice for further analysis regardless of PTPRT genotype. We observed effective chemoprevention in Stattic-treated mice (Wilcoxon P = .0402), with a reduced incidence of severe dysplasia and SCC, and an increased incidence of less advanced disease, resulting in a mean severity score of 2.7 compared to the vehicle mean of 4 ( Figure 3B ). While we observed no statistical effect of PTPRT loss in this model, it is interesting to note that the only two mice that remained disease-free were both PTPRT KO and treated with Stattic (Figure 4) . These tongues also expressed low pSTAT3 and STAT3, suggesting on-target effects of Stattic in these mice. 
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We observed no significant association between severity of disease/Stattic response and protein expression by 
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When considering all mice regardless of PTPRT genotype, we observed effective Stattic-mediated chemoprevention of 4-NQO-mediated oral carcinogenesis (Wilcoxon P = 0.0402), suggesting that targeting Table 2 . Total number of mice that were included for analysis. Parentheses indicate the number of mice that started treatment, while lead numbers indicate total surviving mice that were included in subsequent analyses.
